Clinical Trial: MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional




Official Title: MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)

Brief Summary: The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).